CY2020018I1 - Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων - Google Patents

Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων

Info

Publication number
CY2020018I1
CY2020018I1 CY2020018C CY2020018C CY2020018I1 CY 2020018 I1 CY2020018 I1 CY 2020018I1 CY 2020018 C CY2020018 C CY 2020018C CY 2020018 C CY2020018 C CY 2020018C CY 2020018 I1 CY2020018 I1 CY 2020018I1
Authority
CY
Cyprus
Prior art keywords
modifying agent
adrenal hormone
hormone modifying
adrenal
agent
Prior art date
Application number
CY2020018C
Other languages
English (en)
Other versions
CY2020018I2 (el
Original Assignee
Recordati Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2020018(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ag filed Critical Recordati Ag
Publication of CY2020018I1 publication Critical patent/CY2020018I1/el
Publication of CY2020018I2 publication Critical patent/CY2020018I2/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY2020018C 2010-01-14 2020-07-08 Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων CY2020018I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29498010P 2010-01-14 2010-01-14
PCT/US2011/021100 WO2011088188A1 (en) 2010-01-14 2011-01-13 Use of an adrenal hormone-modifying agent

Publications (2)

Publication Number Publication Date
CY2020018I1 true CY2020018I1 (el) 2020-11-25
CY2020018I2 CY2020018I2 (el) 2020-11-25

Family

ID=43735742

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100096T CY1121320T1 (el) 2010-01-14 2019-01-24 Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων
CY2020018C CY2020018I2 (el) 2010-01-14 2020-07-08 Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191100096T CY1121320T1 (el) 2010-01-14 2019-01-24 Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων

Country Status (33)

Country Link
US (2) US8609862B2 (el)
EP (2) EP3527208A1 (el)
JP (4) JP5602250B2 (el)
KR (1) KR101412206B1 (el)
CN (2) CN102711916B (el)
AU (1) AU2011205290C1 (el)
BR (1) BR112012017458B1 (el)
CA (1) CA2786443C (el)
CL (1) CL2012001961A1 (el)
CY (2) CY1121320T1 (el)
DK (1) DK2523731T3 (el)
ES (1) ES2707596T3 (el)
HR (1) HRP20190064T1 (el)
HU (2) HUE041967T2 (el)
IL (1) IL220804A0 (el)
LT (2) LT2523731T (el)
LU (1) LUC00159I2 (el)
MA (1) MA33904B1 (el)
ME (1) ME03371B (el)
MX (2) MX354022B (el)
NL (1) NL301043I2 (el)
NO (1) NO2020012I1 (el)
NZ (1) NZ601077A (el)
PL (1) PL2523731T3 (el)
PT (1) PT2523731T (el)
RS (1) RS58234B1 (el)
RU (1) RU2598708C2 (el)
SG (1) SG182393A1 (el)
SI (1) SI2523731T1 (el)
TN (1) TN2012000352A1 (el)
TR (1) TR201900515T4 (el)
WO (1) WO2011088188A1 (el)
ZA (1) ZA201205058B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2598708C2 (ru) * 2010-01-14 2016-09-27 Новартис Аг Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников
MX359263B (es) 2010-06-16 2018-09-20 Board Of Supervisors Of Louisiana State Univ & Agricultural & Mechanical College Composiciones y métodos para el tratamiento de adicciones, trastornos psiquiátricos , y enfermedades neurodegenerativas.
AR086665A1 (es) 2011-06-14 2014-01-15 Lilly Co Eli Inhibidor de aldosterona sintasa y composiciones farmaceuticas
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2757883B1 (en) 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
UA114803C2 (uk) * 2012-01-17 2017-08-10 Новартіс Аг ФОРМИ І СОЛІ ДИГІДРОПІРОЛ[1,2-c]ІМІДАЗОЛІЛЬНОГО ІНГІБІТОРА АЛЬДОСТЕРОНСИНТАЗИ АБО АРОМАТАЗИ
MX362533B (es) * 2012-04-12 2019-01-23 Novartis Ag Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
JP6496246B2 (ja) 2012-10-05 2019-04-03 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. アルドステロンシンターゼインヒビター関連用途としてのインドリン化合物
JP2015093832A (ja) * 2013-11-08 2015-05-18 日本メジフィジックス株式会社 放射性ハロゲン標識化合物又はその塩、これを含む医薬
PT3166596T (pt) 2014-07-07 2018-10-19 Novartis Ag Formas farmacêuticas
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
BR112017014706A2 (pt) * 2015-01-29 2018-02-06 Novartis Ag processo para a produção de derivados de imidazol condensado
WO2016164476A2 (en) 2015-04-06 2016-10-13 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
KR20180035797A (ko) * 2015-06-22 2018-04-06 엠베라 뉴로 테라퓨틱스 인코포레이티드 물질 사용 장애, 중독, 및 정신 장애의 치료를 위한 조성물 및 방법
CN110582278B (zh) 2017-03-10 2023-04-18 伊姆贝拉神经疗法公司 药物组合物及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
DE19814087A1 (de) 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
PT1121111E (pt) 1998-10-15 2010-05-17 Imp Innovations Ltd Compostos para o tratamento de perda de peso
IL157363A0 (en) 2001-02-16 2004-02-19 Aventis Pharma Inc Novel heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
JP5138875B2 (ja) 2005-07-19 2013-02-06 株式会社デンソー センサ装置
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
US20090304661A1 (en) 2006-03-16 2009-12-10 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Sceince Method And Composition For Proctecting Neuronal Tissue From Damage Induced By Elevated Glutamate Levels
MX2008015008A (es) * 2006-05-26 2008-12-05 Novartis Ag INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA.
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
JP2010501573A (ja) * 2006-08-25 2010-01-21 ノバルティス アクチエンゲゼルシャフト アルドステロン合成酵素および/または11−β−ヒドロキシラーゼおよび/またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体
EP2121652A1 (en) * 2006-12-18 2009-11-25 Novartis AG 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
RU2598708C2 (ru) * 2010-01-14 2016-09-27 Новартис Аг Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников
UA114803C2 (uk) * 2012-01-17 2017-08-10 Новартіс Аг ФОРМИ І СОЛІ ДИГІДРОПІРОЛ[1,2-c]ІМІДАЗОЛІЛЬНОГО ІНГІБІТОРА АЛЬДОСТЕРОНСИНТАЗИ АБО АРОМАТАЗИ
MX362533B (es) * 2012-04-12 2019-01-23 Novartis Ag Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.

Also Published As

Publication number Publication date
RS58234B1 (sr) 2019-03-29
NL301043I2 (nl) 2020-07-06
JP2018150326A (ja) 2018-09-27
NZ601077A (en) 2014-07-25
CN102711916A (zh) 2012-10-03
RU2598708C2 (ru) 2016-09-27
US8609862B2 (en) 2013-12-17
BR112012017458A2 (pt) 2017-12-19
IL220804A0 (en) 2012-08-30
CN102711916B (zh) 2015-09-02
JP2013517280A (ja) 2013-05-16
TN2012000352A1 (en) 2014-01-30
US9434754B2 (en) 2016-09-06
BR112012017458B1 (pt) 2020-10-20
CY1121320T1 (el) 2020-05-29
CY2020018I2 (el) 2020-11-25
MX354022B (es) 2018-02-08
AU2011205290C1 (en) 2014-11-06
LT2523731T (lt) 2019-02-11
HUE041967T2 (hu) 2019-06-28
CN105440038A (zh) 2016-03-30
ES2707596T3 (es) 2019-04-04
EP2523731A1 (en) 2012-11-21
PT2523731T (pt) 2019-01-21
LUC00159I2 (el) 2021-07-06
SI2523731T1 (sl) 2019-02-28
RU2012134510A (ru) 2014-02-20
KR101412206B1 (ko) 2014-06-25
CL2012001961A1 (es) 2013-03-22
MA33904B1 (fr) 2013-01-02
HUS000508I2 (hu) 2021-03-29
ME03371B (me) 2020-01-20
LTPA2020512I1 (lt) 2020-07-27
AU2011205290B2 (en) 2014-06-26
JP5602250B2 (ja) 2014-10-08
JP6181610B2 (ja) 2017-08-16
NO2020012I1 (no) 2020-06-09
TR201900515T4 (tr) 2019-02-21
DK2523731T3 (en) 2019-02-04
LTC2523731I2 (lt) 2022-05-10
EP3527208A1 (en) 2019-08-21
SG182393A1 (en) 2012-08-30
EP2523731B1 (en) 2018-10-24
KR20120116482A (ko) 2012-10-22
CA2786443A1 (en) 2011-07-21
US20140171392A1 (en) 2014-06-19
JP6425688B2 (ja) 2018-11-21
JP2015013859A (ja) 2015-01-22
MX2012008212A (es) 2012-08-03
US20120295888A1 (en) 2012-11-22
NL301043I1 (nl) 2020-06-17
AU2011205290A1 (en) 2012-08-02
HUS2000018I1 (hu) 2020-07-28
PL2523731T3 (pl) 2019-04-30
CA2786443C (en) 2018-12-11
LUC00159I1 (el) 2020-06-16
WO2011088188A1 (en) 2011-07-21
HRP20190064T1 (hr) 2019-03-08
JP2017002063A (ja) 2017-01-05
ZA201205058B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
CY2020018I2 (el) Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων
SMT201500291B (it) Nuovi agenti antimalarici
DK3590934T3 (da) Pyrazolylquinoxalinkinasehæmmere
DK2542600T3 (da) Vandige polyurethandispersioner
DK2525798T3 (da) Anæstetisk formulering
IT1399961B1 (it) Dispositivo divaricatore interspinoso
BR112013009711A2 (pt) agente reticulante
FI9160U1 (fi) Pinnoituslaite
BR112012021749A2 (pt) processos e compostos
DK2402077T3 (da) Isolatorenhed
DE112011102778A5 (de) Magnetovariationales Verfahren
ITGE20110047A1 (it) Miscelatore
BR112013014710A2 (pt) entrega de compostos funcionais
FR2981560B1 (fr) Urinoir mobile
DK2580396T3 (da) Ankerindretning
PL2363354T3 (pl) Dozownik substancji czynnej
ES1071715Y (es) Aposito
UA21042S (uk) Комплект бланків
ITGE20110048A1 (it) Miscelatore
FI20105285A0 (fi) Sekoitin
TH1001001351B (th) ไมโครพาร์ติเคิลนิโคติน-เคลย์ (Nicotine-clay microparticles)
IT1400965B1 (it) Polimorfi di fexofenadina
GB201009342D0 (en) Use of steroid compounds
FI20100324A0 (fi) Vastavoiman hyödyksikäyttö
FI20100084A0 (fi) Vastavoiman hyödyksikäyttö